Key Highlights

  • Altimmune (NASDAQ:ALT) fell 16.58% at the close on Thursday, November 12, 2026, after reporting third quarter results.
  • The net loss was USD 31.6 million, up from USD 19.0 million a year earlier.
  • Pemvidutide, the company's experimental drug for serious liver disease, is in a late-stage MASH trial described as progressing as planned, with main results expected in 2029.
  • The cash balance was not available in the material reviewed, so the funding runway to 2029 is the main open question.

What Altimmune Reported

Altimmune (NASDAQ:ALT) reported a third quarter net loss of USD 31.6 million, compared with USD 19.0 million in the same period a year earlier, an increase of about two thirds. The stock fell as much as 13.73% by 3:02 PM Eastern and closed down 16.58%. The company's lead candidate is pemvidutide, an experimental drug for serious liver disease, and a summary of the update said the late-stage trial in MASH, a fatty liver condition with inflammation and scarring, is progressing as planned, with main results expected in 2029. Investors had hoped for earlier data, so the long timeline weighed on the shares. The loss widened as development spending rose, which is typical when a trial enrolls patients, and it matters because a company with no product Revenue must fund years of expenses before data arrive. The material reviewed did not include the cash balance, so it is not possible to say how long the funds can last.

Why 2029 Is a Hard Date

Three years is a long wait for a small biotechnology company. A late-stage trial in MASH requires many patients and long follow-up to show an effect on liver outcomes, which explains the timeline, but it leaves the stock without a major data event for years. In the meantime the company must raise capital, probably more than once, and each raise dilutes existing holders. A widening loss, from USD 19.0 million to USD 31.6 million, accelerates the need. The obesity and liver disease field is also crowded, with large pharmaceutical groups developing competing treatments, so a delay may allow rivals to reach the market first. Investors in early obesity and liver stories often trade on interim readouts, and when those do not exist, the stock can drift. A decline of 16.58% in a day suggests the market rethought how much value to assign to a program that will not read out for three years.

What Investors Should Look For

For holders of Altimmune (NASDAQ:ALT), the priorities are the cash position and runway, any interim analysis that might be planned before 2029, the pace of enrollment, and the possibility of partnership. A partner with deep resources could fund the trial and reduce dilution, but it would also take a share of any later profits. Investors should read the Quarterly Report for Operating Expense by function, because research costs will rise as the trial moves into full enrollment. They should also check safety data, since tolerability determines whether a drug can be used long term. Weak sentiment in health care, which fell 0.59% on Thursday, added to the pressure. The shares may stay volatile, so position sizing matters. A clear plan to extend funding or to deliver data earlier would be the strongest positive catalyst for the stock. Investors should also consider the competitive landscape, since several large drug makers are advancing incretin-based therapies for liver disease and obesity, and any positive data from a rival could reset expectations for what Altimmune must show in its own trial to be competitive on efficacy, tolerability and dosing convenience.

Where Things Stand

The company lost USD 31.6 million in the quarter, kept its late-stage trial on schedule and pointed to 2029 for main results, and the shares fell 16.58%. Cash runway and funding are the central issues. Altimmune (NASDAQ:ALT) investors should expect dilution risk and look for any interim data plan in coming updates.